Study: Teprotumumab for patients with active thyroid eye disease
20 Apr, 2021 | 05:25h | UTCTeprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)